Investor Ideas #Potcasts, #Cannabis News and #Stocks on the Move; (CSE: $DIXI_U.C) (OTCQX: $DXBRF) (CSE: $AUSA.C) (CSE: $BEV.C)
Delta, Kelowna, BC, January 16, 2020 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today’s podcast edition of cannabis news and stocks to watch plus insight from thought leaders and experts.
Listen to the podcast:
Read this in full at
Today’s podcast overview/transcript:
Good afternoon and welcome to another episode of Investorideas.com "Potcast" featuring cannabis news, stocks to watch as well as insights from thought leaders and experts.
In today’s podcast we look at a few early announcements.
But first, The Medical Cannabis Clinics, recently CQC registered, is the UK's largest and fastest growing chain of private cannabis clinics, with doctors now operating from seven locations across the country and more openings planned over the coming months to meet patient demand.
Through working in collaboration with the global leaders in medical cannabis education and training, The Academy of Medical Cannabis, the clinic chain has amassed a team of skilled clinicians who have been trained to prescribe cannabis-based medicine.
The demand for cannabinoid medicine has never been more evident after this week's release of a YouGov poll suggesting a staggering 1.4 million British citizens are resorting to using cannabis illegally in an attempt to treat a range of conditions and symptoms.
According to Jonathan Nadler, Group MD at LYPHE Group: "Patients should be able to access legal medical cannabis but both advocates and doctors have been thoroughly dissatisfied with the lack of progress since cannabis was rescheduled in 2018. Many were outraged when NICE issued their latest recommendations a couple of months ago in which only two cannabis-based drugs, Epidyolex and Sativex, were recommended for use by those suffering from either rare forms of childhood-onset epilepsy or spasticity related to multiple sclerosis. This update left many, including patients suffering from other conditions like fibromyalgia and chronic pain, feeling snubbed by the healthcare institute and the medical community as a whole. NICE's guidance is often taken as gospel by healthcare professionals who won't prescribe without its explicit authorisation."
However the NICE guidance does not override the responsibility of healthcare professionals to carefully assess and assign the appropriate line of treatment in their patients' best interests. So, through asserting the right to their own clinical discretion around their patient's treatment and care, specialists are now taking back their power to prescribe, providing high quality and effective medical cannabis care in the process.
The guidelines specifically state: 'Once NICE guidance is published, health professionals are expected to take it fully into account when exercising their clinical judgement. However, NICE guidance does not override the individual responsibility of health professionals to make appropriate decisions according to the circumstances of the individual patient in consultation with the patient and / or their guardian or carer.'
Jonathan Nadler added: "Doctors operating with The Medical Cannabis Clinics are not afraid to exercise their knowledge and expertise to write medical cannabis prescriptions for patients who need it. With clinics in London (Harley Street), Birmingham (Solihull), Manchester, Nottingham, Leeds, Newcastle and Bristol, we are proud to be assisting patients across the country."
Dixie Brands Inc. (CSE: DIXI.U) (OTCQX: DXBRF), one of the cannabis industry's leading consumer packaged goods ("CPG") companies, confirmed that, in conjunction with its manufacturer, it will launch Dixie's initial branded product offering into the Oklahoma medical cannabis market by the end of January 2020, meeting its expectation announced in the previous press release related to the Oklahoma expansion. The initial offering will be followed by a full portfolio launch, including Dixie's pioneering CBD brand AcesoHemp, in February 2020.
Dixie, a pioneer in the development of infused-cannabis products since 2010, has built one of the industry's most comprehensive portfolios via a deep R&D and production heritage built over nearly a decade. With over 100 products across more than 15 different product categories, the portfolio represents one of the industry's most extensive 'House of Brands' encompassing both regulated THC and ratio brands in Dixie and Synergy and hemp-derived CBD offerings, including AcesoHemp and Therabis.
Oklahoma is one of the country's fastest growing legal cannabis markets with over 200,000 registered patients driving more than $250 million in regulated retail sales as of October 2019 (source: KUTL, December 4th, 2019). With more than 5% of the state's population now registered as medical cannabis patients, exceeding any other program in the nation, the category was expected to eclipse $350 million by the end of 2019 (Source: Marijuana Business Daily, November 19, 2019). The passing of SQ788 (the bill legalizing cannabis for medical use) provides the opportunity for licensed dispensaries to offer patients both THC and hemp-derived CBD products.
"We are excited to be bringing Dixie's unparalleled portfolio of THC & CBD-infused brands to 200,000 medical patients in the dynamic Oklahoma market" said Chuck Smith, President and CEO, Dixie Brands. "The fact that we are able to bring product to market within 60 days of announcing our licensed manufacturing partner is a testament to the agility and expertise the Dixie Brands team has developed over a decade in business".
The growth of Oklahoma's medical cannabis market to date has been far greater than any other medical market launch. 2019 saw medical patient counts increase eightfold and over 2,000 dispensary licences issued (Source: Marijuana Business Daily, November 19, 2019), providing an exciting early mover opportunity for Dixie's well-established portfolio of brands in this rapidly growing market.
Australis Capital Inc. (CSE: AUSA) (OTC: AUSAF) announced that AUSA's wholly-owned brands Tsunami™, a science-driven recreational extract brand, and GT Flowers, continue to receive industry recognition as leaders in product innovation and quality with wins at the High Times Cannabis Cup Nevada 2019 in a rare four-category sweep: 1st Place Best Indica Concentrates, 1st Place Best Sativa Concentrates, 2nd Place Best Hybrid Concentrates, and 3rd Place Vape Cartridges. As the premier competition in the cannabis industry, the High Times Cannabis Cup spotlights top companies and products in the Nevada cannabis market.
"The great showing at the High Times Cup validates the hard work, creativity and care Green Therapeutics uses when approaching the cultivation and extraction processes," said Dr. Duke Fu, CEO of Green Therapeutics, LLC. "We are proud to have been successful in the manufacturing and creation of differentiated products that bring joy to our customers."
As the cannabis industry continues expanding, consumers are seeking premium-quality cannabis options from quality suppliers. Tsunami™, Provisions™, and GT Flowers answer this demand with high-quality, innovative products, a wide array of phenotypes, and broad distribution through some of the largest dispensaries in Nevada, including Planet 13, The Source, and THRIVE Marketplace. GT Flowers is exclusively sold through The Source and in 2019, Tsunami™ became the exclusive premium extract provider to the only consumption lounge in Nevada.
"These wins along with the growth of AUSA's brands in Nevada prove that marijuana brands built on quality cultivation, extraction, marketing, and management will thrive and grow with the consumer," said Cleve Tzung, SVP of Mergers & Acquisitions at AUSA. "We're very proud of the GT team that was acquired less than a year ago and look forward to introducing our award-winning brands to new markets in the coming months."
Tsunami™, Provisions™, and GT Flowers continue to increase sales, focusing on high turnover SKUs to supply the high volume demands from some of the largest dispensaries in Nevada, while expanding and developing new dispensary partnerships.
Pursuant to a share exchange agreement dated January 13, 2020 with Carmanah and each of the shareholders of Carmanah, the Company has completed the acquisition of all the issued and outstanding securities of Carmanah and the business of Carmanah.
The acquisition of the cannabis genetics expert gives BevCanna access to an extensive library of cannabis genetics, including 50 premium cannabis strains and over 25 types of cannabis seeds, including six auto flower seed varieties. There is an excess of 50 strains by clone and 250,000 cannabis seeds ranging from high THC to high CBD. Additionally, a large portion of the genetics are outdoor-specific strains that originated in California, which boasts a very similar climatic zone to our operations in the Okanagan and are expected to increase yields. The library of genetics includes many of the top mold resistant, outdoor, high yielding, auto flower seeds, many of which are anticipated at 2kg+ of yield per plant. With the addition of such a substantial auto flower library, the harvest times will start much earlier allowing for much more organized final processing.
"This deal will dramatically increase our overall cannabis yield projections." said Joey Bedard-Brunet, Head of Cultivation at BevCanna. "Together with the recently announced increase in our outdoor cannabis cultivable land to almost 300 acres, the acquisition of Carmanah's proven outdoor genetics will allow BevCanna to develop into one of the largest outdoor cannabis cultivators in Canada." said John Campbell, Chief Strategy Officer at BevCanna.
One World Pharma, Inc. (OTCQB: OWPC), a fully licensed pure-play cannabis and hemp ingredient producer in Colombia, has been honored by the Assembly of the Department of Cauca, Colombia for its efforts to invest in, develop and empower the local population in the region. The award is the highest distinction granted by the Assembly, and was approved unanimously by the governing body.
One World Pharma’s mission is to create a leading international cannabis and hemp ingredient company which leverages the extremely beneficial natural conditions in equatorial Colombia with the best interests of the indigenous people in mind. To that end, OWP has put the people of the once troubled State of Cauca first; hiring, training, and partnering hand-in-hand with them in a shared goal to capitalize on the unique Colombian cannabis and hemp opportunity.
The company has already hired a large number of indigenous people and created new opportunities for them to partner in profitable outcomes. In addition, One World Pharma has overseen the construction of new roads, running water and other essential amenities.
“We are proud to walk-the-walk and not just talk-the-talk,” stated Brian Moore, President, One World Pharma. “Our company was and is intent on a business model that lifts others up, changes their lives for the better, and harnesses that goodwill as the driving force to become a real agent of change in Colombia and the international cannabis and hemp marketplace. This award, given by those who know us best, is a testament to our commitment and to the life-changing impact of our devoted team.”
“This is more than just an honor from our friends and partners for a new Colombia,” stated Moore. “It is an affirmation of our pledge to work in partnership with the people who need it most, and to collaborate in this emerging part of Colombia to benefit their people.”
“As we draw ever closer to our first harvests and revenue generating activities, it is heartening to have our core humanitarian mission acknowledged,” added Moore. “The people of Cauca are now closer to living the lives every human deserves.”
Investor ideas reminds all listeners to read our disclaimers and disclosures on the
Investorideas.com website and this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment
Investorideas.com podcasts are also available on iTunes, Spotify, Google Play Music, Stitcher, Spreaker, YouTube via Spreaker, iHeartradio and Tunein.
Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708
About Investorideas.com - News that Inspires Big Investing Ideas
Investorideas.com is a recognized news source publishing third party news, research and original financial content. Learn about investing in stocks and sector trends with our news alerts, articles, podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea’s original branded content includes the following podcasts and columns : Crypto Corner , Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate Change , Exploring Mining the AI Eye .
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info:
Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.
Follow us on Cannabis Social Media
Contact Investorideas.com
800-665-0411
